Clinical Trial Update: Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) [Phase 3]

View source ↗

Summary

Phase 3 CheckMate 067 in previously untreated advanced melanoma compared nivolumab alone or with ipilimumab against ipilimumab alone. Results posted in 2017 sho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Unresectable or Metastatic Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2017-09-26